Biomx Reports First Quarter 2024 Financial Results And Provi

Following merger with Adaptive Phage Therapeutics in March, combined company reports funding sufficient to support important data readouts for lead c

Related Keywords

United States , Israel , American , Israeli , Jonathan Solomon , Action Fund , European Society Of Clinical Microbiology , Drug Administration , Cystic Fibrosis Foundation , Israeli Innovation Authority , Adaptive Phage Therapeutics Inc , Global Congress , Nasdaq , Clinical Program Updates , Biomx Inc , Adaptive Phage Therapeutics , Chief Executive Officer , Top Poster , Deerfield Management , Nantahala Capital , Orphan Drug Designation , United States Food , European Society , Clinical Microbiology , Infectious Diseases , Foot Osteomyelitis ,